<DOC>
	<DOCNO>NCT02675231</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness abemaciclib plus trastuzumab without fulvestrant chemotherapy woman hormone receptor positive ( HR+ ) , human epidermal growth factor receptor 2 positive ( HER2+ ) locally advanced metastatic breast cancer prior exposure least two HER2-directed therapy advance disease .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Women With HR+ , HER2+ Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>diagnosis HR+ , HER2+ breast cancer ( BC ) unresectable locally advanced recurrent BC metastatic BC adequate tumor tissue available prior randomization measurable and/or nonmeasurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 previously receive : least 2 HER2directed therapy advance disease participant must receive trastuzumab emtansine ( TDM1 ) disease set must receive taxane disease setting may receive endocrine therapy ( exclude fulvestrant ) postmenopausal status performance status ( PS ) 0 1 Eastern Cooperative Oncology Group scale leave ventricular ejection fraction ( LVEF ) 50 % high baseline adequate organ function negative serum pregnancy test baseline ( within 14 day prior randomization ) agree use medically approve precaution prevent pregnancy study 12 week follow last dose abemaciclib id menopause induce gonadotropinreleasing hormone ( GnRH ) agonist radiation discontinue previous localize radiotherapy palliative purpose lytic lesion risk fracture least 2 week prior randomization recover acute effect therapy discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , endocrine therapy ) , except trastuzumab , least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy able swallow capsule visceral crisis know central nervous system ( CNS ) metastases untreated , symptomatic , require steroid control symptoms major surgery within 14 day prior randomization receive prior treatment cyclindependent kinase ( CDK ) 4 CDK 6 inhibitor receive treatment drug receive regulatory approval indication within 14 21 day randomization nonmyelosuppressive myelosuppressive agent , respectively serious preexist medical condition , judgment investigator , would preclude participation study history within last 6 month symptomatic congestive heart failure , myocardial infarction , unstable angina history within last 12 month follow condition : syncope cardiovascular etiology , ventricular tachycardia , ventricular fibrillation , sudden cardiac arrest history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy minimum 3 year active bacterial , fungal infection , detectable viral infection receive recent ( within 28 day prior randomization ) live virus vaccination hypersensitivity trastuzumab , murine protein , fulvestrant , excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>